Insulet (PODD)
(Delayed Data from NSDQ)
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Zacks News
Insulet's (PODD) Omnipod DASH System Now ISO 27001 Certified
by Zacks Equity Research
Insulet (PODD) is now the only insulin pump company to be awarded with both the ISO 27001 and the DTSec Cybersecurity Standard for Connected Diabetes Device Security certifications.
Insulet (PODD) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) Q3 results on solid uptake of Omnipod system in the United States. It is also gaining from pursuing direct European operations.
Insulet (PODD) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 50.00% and 1.74%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
by Zacks Equity Research
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
by Zacks Equity Research
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
by Zacks Equity Research
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
4 Top Stocks With the Power of Earnings Acceleration
by Tirthankar Chakraborty
Studies show that a majority of successful stocks see acceleration in earnings before a positive stock price movement.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Insulet (PODD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 76.92% and -6.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark
by Zacks Equity Research
Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.
Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
Integra (IART) Reports In-Line Q2 Earnings, Tapers View
by Zacks Equity Research
Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.
Align Technology (ALGN) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
Boston Scientific (BSX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q2.
Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.
PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid
by Zacks Equity Research
We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.